Twist Bioscience Corporation Common Stock TWST
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T16:05:42.013Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T16:05:27.118617949Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-12T16:05:40.487707+00:00
Twist Bioscience Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 128.60 | 115.9% | 19.2% | 95.35 | 125.4% | 15.2% |
| 25Δ | 125.65 | 120.5% | 17.2% | 98.45 | 123.4% | 13.1% |
| 30Δ | 122.13 | 118.1% | 14.6% | 101.27 | 123.2% | 11.4% |
| 35Δ | 118.87 | 115.6% | 12.2% | 103.83 | 124.9% | 10.1% |
| 40Δ | 116.20 | 115.5% | 10.6% | 106.38 | 125.3% | 8.8% |
| 45Δ | 113.69 | 116.1% | 9.1% | 108.93 | 124.7% | 7.6% |
| 50Δ | 111.29 | 117.4% | 7.9% | 111.49 | 124.0% | 6.5% |
| 55Δ | 108.87 | 118.6% | 6.8% | 114.05 | 123.2% | 5.5% |
| 60Δ | 106.43 | 119.9% | 5.7% | 116.62 | 121.5% | 4.6% |
| 65Δ | 104.03 | 119.3% | 4.7% | 119.19 | 119.3% | 3.7% |
| 70Δ | 101.67 | 116.1% | 3.7% | 122.45 | 120.7% | 3.0% |
| 75Δ | 99.17 | 113.9% | 2.8% | 125.97 | 122.4% | 2.4% |
| 80Δ | 96.37 | 114.0% | 2.1% | 129.38 | 120.0% | 1.7% |
20Δ
- Pseudo strike
- 128.60
- IV
- 115.9%
- B/E move
- 19.2%
- Pseudo strike
- 95.35
- IV
- 125.4%
- B/E move
- 15.2%
25Δ
- Pseudo strike
- 125.65
- IV
- 120.5%
- B/E move
- 17.2%
- Pseudo strike
- 98.45
- IV
- 123.4%
- B/E move
- 13.1%
30Δ
- Pseudo strike
- 122.13
- IV
- 118.1%
- B/E move
- 14.6%
- Pseudo strike
- 101.27
- IV
- 123.2%
- B/E move
- 11.4%
35Δ
- Pseudo strike
- 118.87
- IV
- 115.6%
- B/E move
- 12.2%
- Pseudo strike
- 103.83
- IV
- 124.9%
- B/E move
- 10.1%
40Δ
- Pseudo strike
- 116.20
- IV
- 115.5%
- B/E move
- 10.6%
- Pseudo strike
- 106.38
- IV
- 125.3%
- B/E move
- 8.8%
45Δ
- Pseudo strike
- 113.69
- IV
- 116.1%
- B/E move
- 9.1%
- Pseudo strike
- 108.93
- IV
- 124.7%
- B/E move
- 7.6%
50Δ
- Pseudo strike
- 111.29
- IV
- 117.4%
- B/E move
- 7.9%
- Pseudo strike
- 111.49
- IV
- 124.0%
- B/E move
- 6.5%
55Δ
- Pseudo strike
- 108.87
- IV
- 118.6%
- B/E move
- 6.8%
- Pseudo strike
- 114.05
- IV
- 123.2%
- B/E move
- 5.5%
60Δ
- Pseudo strike
- 106.43
- IV
- 119.9%
- B/E move
- 5.7%
- Pseudo strike
- 116.62
- IV
- 121.5%
- B/E move
- 4.6%
65Δ
- Pseudo strike
- 104.03
- IV
- 119.3%
- B/E move
- 4.7%
- Pseudo strike
- 119.19
- IV
- 119.3%
- B/E move
- 3.7%
70Δ
- Pseudo strike
- 101.67
- IV
- 116.1%
- B/E move
- 3.7%
- Pseudo strike
- 122.45
- IV
- 120.7%
- B/E move
- 3.0%
75Δ
- Pseudo strike
- 99.17
- IV
- 113.9%
- B/E move
- 2.8%
- Pseudo strike
- 125.97
- IV
- 122.4%
- B/E move
- 2.4%
80Δ
- Pseudo strike
- 96.37
- IV
- 114.0%
- B/E move
- 2.1%
- Pseudo strike
- 129.38
- IV
- 120.0%
- B/E move
- 1.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 70.96% | |
| 71.36% | |
| 75.66% | |
| 88.98% | |
| 85.64% | |
| 82.39% | |
| 87.90% | |
| 88.73% | |
| 88.08% | |
| 87.24% | |
| 85.26% | |
| 82.28% | |
| 82.64% | |
| 76.03% | |
| 74.92% | |
| 78.25% | |
| 79.69% | |
| 77.98% | |
| 77.51% | |
| 78.83% | |
| 80.12% | |
| 82.79% | |
| 90.30% | |
| 84.91% | |
| 85.83% | |
| 85.72% | |
| 86.53% | |
| 95.38% | |
| 96.67% | |
| 97.39% | |
| 93.82% | |
| 94.84% | |
| 93.59% | |
| 91.43% | |
| 94.73% | |
| 90.35% | |
| 85.66% | |
| 85.23% | |
| 84.87% | |
| 89.68% | |
| 90.83% | |
| 93.14% | |
| 96.83% | |
| 90.31% | |
| 90.28% | |
| 91.25% | |
| 91.71% | |
| 96.25% | |
| 96.22% | |
| 96.33% | |
| 94.59% | |
| 102.93% | |
| 102.14% | |
| 103.87% |
Biotechnology
TYRA
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and improve outcomes for cancer patients. The…
More →UNCY
Unicycive Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on pioneering therapies for kidney diseases, particularly in the management of hyperphosphatemia.…
More →UPB
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is…
More →URGN
Description unavailable
More →VANI
Vivani Medical Inc. (VANI) is a pioneering biotechnology firm focused on revolutionizing chronic disease management through its cutting-edge drug delivery systems. The company…
More →VCEL
Description unavailable
More →